Tag Archives: major adverse cardiovascular events (MACE)

Introduction The management of coronary artery disease (CAD) in patients presenting with acute coronary syndromes (ACS) poses a significant challenge in interventional cardiology.1 As clinical practice evolves, the imperative to compare the outcomes of drug-coated balloons (DCB) and drug-eluting stents (DES) has gained prominence, particularly considering the distinct pathophysiological characteristics and risks associated with ACS.2 Insights from the BASKET-SMALL 2 trial, the largest randomised clinical trial assessing DCB versus DES for small-vessel CAD, provide pivotal evidence in this area. This prespecified analysis yielded three signifi